Boston Trust Walden Corp reduced its position in Chemed Corporation (NYSE:CHE - Free Report) by 4.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 191,501 shares of the company's stock after selling 9,774 shares during the period. Chemed comprises about 0.8% of Boston Trust Walden Corp's holdings, making the stock its 26th largest position. Boston Trust Walden Corp owned approximately 1.47% of Chemed worth $96,721,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in CHE. Quantbot Technologies LP bought a new stake in shares of Chemed in the 2nd quarter valued at approximately $1,726,000. The Manufacturers Life Insurance Company acquired a new position in Chemed in the second quarter worth approximately $4,413,000. Lone Peak Global Investors LLC increased its holdings in Chemed by 38.1% in the second quarter. Lone Peak Global Investors LLC now owns 37,099 shares of the company's stock worth $17,279,000 after buying an additional 10,226 shares during the last quarter. Hsbc Holdings PLC raised its position in Chemed by 41.7% during the second quarter. Hsbc Holdings PLC now owns 12,346 shares of the company's stock valued at $5,729,000 after acquiring an additional 3,632 shares in the last quarter. Finally, Amundi raised its position in Chemed by 51.5% during the second quarter. Amundi now owns 53,856 shares of the company's stock valued at $25,083,000 after acquiring an additional 18,301 shares in the last quarter. 95.85% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
CHE has been the subject of a number of analyst reports. Weiss Ratings upgraded shares of Chemed from a "hold (c)" rating to a "hold (c+)" rating in a research note on Thursday, October 8th. Royal Bank Of Canada increased their price target on shares of Chemed from $548.00 to $585.00 and gave the stock a "sector perform" rating in a research note on Thursday, October 29th. Wall Street Zen upgraded shares of Chemed from a "buy" rating to a "strong-buy" rating in a report on Saturday, October 10th. UBS Group raised their price target on shares of Chemed from $650.00 to $675.00 and gave the company a "buy" rating in a report on Thursday, October 29th. Finally, Oppenheimer lifted their price objective on shares of Chemed from $590.00 to $625.00 and gave the company an "outperform" rating in a research note on Thursday, October 29th. Three investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $603.00.
Get Our Latest Stock Report on CHE
Chemed Stock Up 2.9%
Shares of CHE stock opened at $548.87 on Thursday. The stock's 50 day simple moving average is $514.63 and its 200 day simple moving average is $464.29. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.08 and a current ratio of 1.11. Chemed Corporation has a twelve month low of $365.20 and a twelve month high of $562.24. The company has a market capitalization of $7.15 billion, a price-to-earnings ratio of 26.26, a PEG ratio of 2.03 and a beta of 0.50.
Chemed (NYSE:CHE - Get Free Report) last posted its earnings results on Tuesday, October 27th. The company reported $6.75 earnings per share for the quarter, topping the consensus estimate of $6.44 by $0.31. The firm had revenue of $690.94 million during the quarter, compared to analyst estimates of $685.04 million. Chemed had a return on equity of 35.18% and a net margin of 10.61%. The company's revenue for the quarter was up 10.6% on a year-over-year basis. During the same period in the previous year, the company earned $5.27 EPS. As a group, research analysts predict that Chemed Corporation will post 24.05 EPS for the current year.
Insider Buying and Selling
In related news, EVP Spencer S. Lee sold 1,000 shares of the company's stock in a transaction on Friday, August 21st. The shares were sold at an average price of $541.04, for a total transaction of $541,040.00. Following the completion of the sale, the executive vice president directly owned 13,912 shares of the company's stock, valued at approximately $7,526,948.48. This represents a 6.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kevin J. Mcnamara sold 2,000 shares of the firm's stock in a transaction on Monday, September 28th. The shares were sold at an average price of $513.45, for a total transaction of $1,026,900.00. Following the completion of the transaction, the chief executive officer owned 66,418 shares in the company, valued at $34,102,322.10. The trade was a 2.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 7,920 shares of company stock worth $4,147,256. Insiders own 3.33% of the company's stock.
Chemed Company Profile
(
Free Report)
Chemed Corporation NYSE: CHE is a Cincinnati, Ohio-based company that provides healthcare and residential and commercial services through two operating businesses: VITAS Healthcare and Roto-Rooter. Its operations serve customers primarily in the United States, with Roto-Rooter also providing services in Canada.
VITAS Healthcare is a provider of hospice and palliative care for individuals with advanced illnesses. The business delivers care in patients' homes, hospice inpatient units, hospitals, nursing facilities and other care settings.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Chemed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.
While Chemed currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.